Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
semaglutide + ziltivekimab
- Development stage
- Unknown
- Lead developer
- Novo Nordisk
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Peptides
- Administration
- Subcutaneous
01
Overview
NNC0487-0111 + B10145 is a combination therapy developed by **Novo Nordisk** for the treatment of **obesity** and **knee osteoarthritis**. The combination consists of **semaglutide** (NNC0487-0111), a long-acting **glucagon-like peptide-1 (GLP-1) receptor agonist**, and **ziltivekimab** (B10145/NNC0480-0389), a human monoclonal antibody that targets the **interleukin-6 (IL-6)** ligand. Semaglutide promotes weight loss by increasing satiety and reducing caloric intake, while ziltivekimab targets the inflammatory pathways mediated by IL-6, which are implicated in the pathogenesis and pain of osteoarthritis. By combining metabolic control with targeted anti-inflammatory action, the therapy aims to provide enhanced symptomatic relief and potentially modify disease progression in patients with obesity-related knee osteoarthritis.
- Other names
- semaglutide + NNC0480-0389
02
Targets
CALCR (Calcitonin receptor)IL-6 (Interleukin 6)AMY receptor (Calcitonin receptor (with ramps))GLP1R (GLP-1R)
Beyond the preview
Go deeper on semaglutide + ziltivekimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on semaglutide + ziltivekimab.